A BOLD way to treat VVC
A broad-spectrum* triterpenoid antifungal with fungicidal activity1
BREXAFEMME, a non-azole, works by inhibiting glucan synthase.1
- Fungicidal activity kills Candida1*
- Compromises fungal cell wall integrity1
- The same mechanism as echinocandins, which have been established as first-line treatment for invasive Candida infections in the hospital setting3,4
Based on in vitro studies. Clinical significance is unknown.
BREXAFEMME demonstrated in vitro activity against all Candida species that cause VVC, including azole-resistant strains.1
Illustration of Candida albicans.
A truly unique MOA in the treatment of VVC
BREXAFEMME is the only FDA-approved treatment for vaginal yeast infections that is fungicidal.1
Active against all Candida species, with attributes suited to the vaginal environment*
THE ANTIFUNGAL ATTRIBUTES OF BREXAFEMME1
Clinical efficacy shown vs Candida albicans | ![]() |
---|---|
In vitro activity vs non-albicans Candida | ![]() |
In vitro activity vs azole-resistant strains | ![]() |
Exceptional vaginal tissue penetration† | ![]() |
Retains activity in low pH‡ | ![]() |
Based on in vitro studies. Clinical significance is unknown.
In animal studies, BREXAFEMME exhibited exceptional vaginal tissue penetration after oral administration—reaching up to 9 times the plasma concentration.1
BREXAFEMME retained in vitro antifungal activity based on minimal inhibitory concentration values when tested at pH 4.5 (the normal vaginal pH).1